 Connection
Douglas Seals to Enzyme Inhibitors
This is a "connection" page, showing publications Douglas Seals has written about Enzyme Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.288 |
|
|
|
-
Jalal DI, Decker E, Perrenoud L, Nowak KL, Bispham N, Mehta T, Smits G, You Z, Seals D, Chonchol M, Johnson RJ. Vascular Function and Uric Acid-Lowering in Stage 3 CKD. J Am Soc Nephrol. 2017 03; 28(3):943-952.
Score: 0.109
-
Lesniewski LA, Connell ML, Durrant JR, Folian BJ, Anderson MC, Donato AJ, Seals DR. B6D2F1 Mice are a suitable model of oxidative stress-mediated impaired endothelium-dependent dilation with aging. J Gerontol A Biol Sci Med Sci. 2009 Jan; 64(1):9-20.
Score: 0.065
-
Donato AJ, Eskurza I, Jablonski KL, Gano LB, Pierce GL, Seals DR. Cytochrome P-450 2C9 signaling does not contribute to age-associated vascular endothelial dysfunction in humans. J Appl Physiol (1985). 2008 Oct; 105(4):1359-63.
Score: 0.062
-
Eskurza I, Kahn ZD, Seals DR. Xanthine oxidase does not contribute to impaired peripheral conduit artery endothelium-dependent dilatation with ageing. J Physiol. 2006 Mar 15; 571(Pt 3):661-8.
Score: 0.052
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|